# Tucatinib after isolated brain progression

Source: https://onco.cc/trials/nct05323955/  
OnCo record `nct05323955` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study adds tucatinib after local treatment for cancer progression in the brain while continuing selected HER2-directed therapy. It follows further progression in people whose cancer outside the brain remains controlled.

## Summary

This study adds tucatinib after local treatment for cancer progression in the brain while continuing selected HER2-directed therapy. It follows further progression in people whose cancer outside the brain remains controlled.

Interventional study registered as NCT05323955, sponsored by Carey Anders, M.D.. Registry phase: 2. Registry enrollment is 48 participants (estimated). Registry status checked October 10, 2026: active not recruiting. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-10
- Also known as: Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
- Tags: ucsf-breast-coverage; interventional
- Registry id: NCT05323955
- Phase: 2
- Setting: Advanced HER2-positive breast cancer with isolated intracranial progression
- Sponsor: Carey Anders, M.D.

## Sources

- ClinicalTrials.gov NCT05323955: https://clinicaltrials.gov/study/NCT05323955
- UCSF study listing and local availability: https://clinicaltrials.ucsf.edu/trial/NCT05323955

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Pertuzumab](https://onco.cc/drugs/pertuzumab/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Trastuzumab emtansine](https://onco.cc/drugs/trastuzumab-emtansine/), [Tucatinib](https://onco.cc/drugs/tucatinib/)
- institutions: [UCSF Helen Diller Family Comprehensive Cancer Center](https://onco.cc/institutions/ucsf/)

---
JSON: https://onco.cc/api/v1/entities/nct05323955.json